Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey

被引：0

作者：

Levra, M. Giaj ^{[1
]}

Benet, J. ^{[1
]}

Hasan, B. ^{[2
]}

Berghmans, T. ^{[3
]}

Bruni, A. ^{[4
]}

Dingemans, A. M. ^{[5
]}

Levra, N. Giaj ^{[6
]}

Edwards, J. ^{[7
]}

Faivre-Finn, C. ^{[8
]}

Girard, N. ^{[9
]}

Gobbini, E. ^{[1
]}

Greillier, L. ^{[10
]}

Hendriks, L. ^{[5
]}

Lantuejoul, S. ^{[11
]}

Levy, A. ^{[12
]}

Novello, S. ^{[13
]}

O'Brien, M. ^{[14
]}

Reck, M. ^{[15
]}

Pochesci, A. ^{[2
]}

Menis, J. ^{[16
]}

Besse, B. ^{[12
]}

机构：

[1] CHU Grenoble, La Tronche, France

[2] Eortc, Brussels, Belgium

[3] Inst Jules Bordet, Brussels, Belgium

[4] Univ Hosp Modena, Dept Oncol & Hematol, Modena, Italy

[5] Maastricht Univ, Med Ctr, Maastricht, Netherlands

[6] Irccs Sacro Cuore Don Calabria Hosp, Negrar, Radiotherapy Unit, Verona, Italy

[7] Northern Gen Hosp, Sheffield, S Yorkshire, England

[8] Christie Univ Manchester, Dept Radiotherapy Related Res, Manchester, Lancs, England

[9] Inst Curie, Paris, France

[10] Ap Marseille, Serv Oncol Multidisciplinaire & Innovat Therapeut, Marseille, France

[11] Ctr Leon Berard, Lyon, France

[12] Inst Gustave Roussy, Villejuif, France

[13] Univ Turin, Dept Oncol, San Luigi Gonzaga Hosp, Orbassano, Italy

[14] Royal Marsden, London, England

[15] Lungen Clin, Grosshansdorf, Germany

[16] Iov, Padua, Italy

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期

关键词：

durvalumab; stage III NSCLC; treatment strategy;

D O I：

10.1016/j.jtho.2019.08.557

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA08.02

引用

页码：S277 / S278

页数：2

共 50 条

[1] An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer
Houda, I.
Bahce, I.
Dickhoff, C.
Kroese, T. E.
Kroeze, S. G. C.
Mariolo, A. V.
Tagliamento, M.
Moliner, L.
Brandao, M.
Edwards, J.
Opitz, I.
Faivre-Finn, C.
de Ruysscher, D.
Remon, J.
Berghmans, T.
Dingemans, A. -M. C.
Besse, B.
Hendriks, L. E. L.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S55 - S56
[2] Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer
Tomasini, Pascale
Greillier, Laurent
Boyer, Arnaud
Jeanson, Arnaud
Barlesi, Fabrice
[J]. JOURNAL OF THORACIC DISEASE, 2018, 10 : S1032 - S1036
[3] Is durvalumab the solution for unresectable stage III non-small cell lung cancer?
Duma, Narjust
Mansfield, Aaron S.
[J]. TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S89 - S93
[4] RADIOTHERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)
De Ruysscher, D.
[J]. LUNG CANCER, 2009, 64 : S21 - S21
[5] Definition of Resectable Stage III Non-Small Cell Lung Cancer: A Systematic Review from EORTC Lung Cancer Group
Xenophontos, E.
Levra, N. Giaj
Durieux, V.
Van Geffen, W.
Grisay, G.
De la Pinta Alonso, C.
Arasanz Esteban, H.
Prisciandaro, E.
Ferrara, R.
Derks, J.
Von der Thusen, J.
Dickhoff, C.
Brandao, M.
Faivre-Finn, C.
Edwards, J.
De Ruysscher, D.
Remon, J.
Dingemans, A. -M.
Berghmans, T.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S292 - S292
[6] Durvalumab for the treatment of non-small cell lung cancer
Murakami, Shuji
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (12) : 1009 - 1016
[7] Durvalumab for the treatment of non-small cell lung cancer
Mezquita, Laura
Planchard, David
[J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2018, 12 (08) : 627 - 639
[8] COST-EFFECTIVENESS OF DURVALUMAB AFTER CHEMORADIATION IN STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)
Criss, S. D.
Mooradian, M. J.
Lumish, M. A.
Reynolds, K. L.
Kong, C. Y.
[J]. VALUE IN HEALTH, 2018, 21 : S12 - S12
[9] Importance of the Multidisciplinary Tumor Board in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC)
Benet, J.
Toffart, A. C.
Frey, G.
Chollier, T.
Ruckly, S.
Villa, J.
Emprou, C.
Pinsolle, J.
Dumas, I.
Guillem, P.
Ferretti, G.
Moro-Sibilot, D.
Levra, M. Giaj
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S906 - S906
[10] Durvalumab after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC) - a German radiation oncology survey
Kaesmann, Lukas
Eze, Chukwuka
Taugner, Julian
Roengvoraphoj, Olarn
Belka, Claus
Manapov, Farkhad
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

← 1 2 3 4 5 →